Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Has A Couple Of Controversies To Cover During Earnings Call

Executive Summary

Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30. 

You may also be interested in...



Lilly Says Volume Growth Strategy, Launches Working Despite Price Pressures

Trulicity, Taltz grew in the first quarter, but below analyst consensus estimates. Company points to price decreases as holding down growth.

Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125118

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel